First Trust Direct Indexing L.P. Has $3.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

First Trust Direct Indexing L.P. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,381 shares of the biopharmaceutical company’s stock after buying an additional 97 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in Regeneron Pharmaceuticals were worth $3,254,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $932,571,000. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after acquiring an additional 590,314 shares during the period. Global Assets Advisory LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter worth about $339,594,000. First Trust Advisors LP grew its stake in shares of Regeneron Pharmaceuticals by 115.2% in the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares during the period. Finally, abrdn plc grew its stake in shares of Regeneron Pharmaceuticals by 552.8% in the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after purchasing an additional 186,215 shares during the period. 83.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd. JPMorgan Chase & Co. boosted their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. Finally, TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,027.55.

Regeneron Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ:REGN traded down $20.57 during mid-day trading on Thursday, reaching $1,024.09. The stock had a trading volume of 378,341 shares, compared to its average volume of 459,242. The firm has a 50 day simple moving average of $992.50 and a two-hundred day simple moving average of $954.60. Regeneron Pharmaceuticals, Inc. has a twelve month low of $688.52 and a twelve month high of $1,081.17. The firm has a market cap of $112.84 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 2.16 and a beta of 0.13. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at $457,179,964.71. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,467,684. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,208 shares of company stock worth $62,514,142. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.